Conference Reports

Pasay City
22 May 2019 - 26 May 2019
Lisbon, Portugal
17 March 2019 - 19 March 2019
New Orleans, Louisiana
16 March 2019 - 18 March 2019
Honolulu, Hawaii, US
06 February 2019 - 08 February 2019
Kuala Lumpur
18 January 2019 - 20 January 2019
Kuala Lumpur
22 November 2018 - 25 November 2018
Chicago, Illinois, US
10 November 2018 - 12 November 2018
San Diego, California, US
21 September 2018 - 25 September 2018
Bangkok, Thailand
28 September 2018 - 01 October 2018
Munich
25 August 2018 - 29 August 2018
Barcelona
18 March 2018 - 20 March 2018
Orlando, Florida
10 March 2018 - 12 March 2018
Los Angeles, California, US
24 January 2018 - 26 January 2018
Abu Dhabi
04 December 2017 - 08 December 2017
Anaheim, California, US
11 November 2017 - 15 November 2017
Singapore
20 October 2017 - 21 October 2017
Singapore
06 October 2017 - 08 October 2017
Barcelona
26 August 2017 - 30 August 2017
Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
12 November 2016 - 16 November 2016
Yangon
14 October 2016 - 16 October 2016
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 5 days ago
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Dr Margaret Shi, 4 days ago

A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.